We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Henry Schein (HSIC) Tops Q2 Earnings and Revenues Estimate
Read MoreHide Full Article
Headquartered in Melville, NY, Henry Schein Inc. (HSIC - Free Report) is a global leading provider of healthcare products and services. The company serves office-based dental, medical and animal health practitioners, dental laboratories, government as well as institutional health care clinics and other alternate-care sites. Presently, Henry Schein serves more than 1 million customers and has operations in 28 countries. The company entered the prestigious Standard & Poor's (S&P) 500 Index in Mar, 2015.
Currently, Henry Schein has a Zacks Rank #2 (Buy) but that could change following its second quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.)We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate remained steady at $1.73 per share over the last 60 days. Henry Schein’s adjusted earnings per share of $1.75 beat this estimate by a couple of cents.
Revenues: Henry Schein posted revenues of $3.05 billion, ahead of the Zacks Consensus Estimate for revenues of $3.04 billion.
Key Stats: Revenues in the second quarter derived from Henry Schein’s Dental segment grew 8.4% year over year to $1.48 billion, while Animal Health segment recorded sales of $891.3 million, up 4.4% compared with the prior-year quarter. Revenues from Medical segment increased 6.1% year over year to $571.4 million, while sales from Technology and Value-added services segment grew 1.4% to $108.5 million.
Major Factors: Per management, its four global segments gained solid market share during the quarter and delivered solid earnings growth on back of the strategy to grow the business organically and through acquisitions. The company reaffirmed adjusted EPS guidance for 2017.
Stock Price: Following the earnings release, share prices did not show any significant movement in the pre-market trading session.
Check back later for our full write up on this Henry Schein earnings report later!
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Henry Schein (HSIC) Tops Q2 Earnings and Revenues Estimate
Headquartered in Melville, NY, Henry Schein Inc. (HSIC - Free Report) is a global leading provider of healthcare products and services. The company serves office-based dental, medical and animal health practitioners, dental laboratories, government as well as institutional health care clinics and other alternate-care sites. Presently, Henry Schein serves more than 1 million customers and has operations in 28 countries. The company entered the prestigious Standard & Poor's (S&P) 500 Index in Mar, 2015.
Currently, Henry Schein has a Zacks Rank #2 (Buy) but that could change following its second quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.)We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate remained steady at $1.73 per share over the last 60 days. Henry Schein’s adjusted earnings per share of $1.75 beat this estimate by a couple of cents.
Revenues: Henry Schein posted revenues of $3.05 billion, ahead of the Zacks Consensus Estimate for revenues of $3.04 billion.
Key Stats: Revenues in the second quarter derived from Henry Schein’s Dental segment grew 8.4% year over year to $1.48 billion, while Animal Health segment recorded sales of $891.3 million, up 4.4% compared with the prior-year quarter. Revenues from Medical segment increased 6.1% year over year to $571.4 million, while sales from Technology and Value-added services segment grew 1.4% to $108.5 million.
Henry Schein, Inc. Price and EPS Surprise
Henry Schein, Inc. Price and EPS Surprise | Henry Schein, Inc. Quote
Major Factors: Per management, its four global segments gained solid market share during the quarter and delivered solid earnings growth on back of the strategy to grow the business organically and through acquisitions. The company reaffirmed adjusted EPS guidance for 2017.
Stock Price: Following the earnings release, share prices did not show any significant movement in the pre-market trading session.
Check back later for our full write up on this Henry Schein earnings report later!
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>